Format

Send to

Choose Destination
Account Res. 2014;21(6):389-400. doi: 10.1080/08989621.2014.882780.

Blood money: Bayer's inventory of HIV-contaminated blood products and third world hemophiliacs.

Author information

1
a Department of Philosophy , California State University , Ns , California , USA.

Abstract

This article presents an overlooked case of research misconduct and violations of basic principles of medical and business ethics. When Bayer's Cutter Laboratories realized that their blood products, Factor VIII and IX or antihemophiliac factor (AHF), were contaminated with human immunodeficiency virus (HIV), the financial investment in the product was considered too high to destroy the inventory. Cutter misrepresented the results of its own research and sold the contaminated AHF to overseas markets in Asia and Latin America without the precaution of heat treating the product recommended for eliminating the risk. As a consequence, hemophiliacs who infused the HIV-contaminated Factor VIII and IX tested positive for HIV and developed AIDS.

KEYWORDS:

AIDS; Bayer; Cutter Laboratories; Third World; antihemophiliac factor (AHF); hemophilia; hepatitis; human immunodeficiency virus (HIV)

PMID:
24785997
DOI:
10.1080/08989621.2014.882780
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center